Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Current Opinion in Infectious Diseases|October 7, 2022
Empirical antibiotic therapy for difficult-to-treat Gram-negative infections: when, how, and how long?Matteo Bassetti, Antonio Vena, Laura Labate, et al.Current Opinion in Infectious Diseases|January 6, 2021
Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indicationsMatteo Bassetti, Laura Labate, Antonio Vena, et al.Current Opinion in Infectious Diseases|January 4, 2021
Potential role of new-generation antibiotics in acute bacterial skin and skin structure infectionsDaniele R Giacobbe, Laura Labate, Antonio Vena, et al.Infectious Diseases & Immunity|June 22, 2026
Epidemiology, clinical overview, and potential risk of a new pandemic of measles virusMatteo Bassetti, Daniele Roberto Giacobbe, Chiara Sepulcri, et al.Expert Opinion on Pharmacotherapy|September 11, 2020
Therapeutic options for difficult-to-treat A<i>cinetobacter baumannii</i> infections: a 2020 perspectiveMatteo Bassetti, Laura Labate, Chiara Russo, et al.The New Microbiologica|May 2, 2025
Two-drug regimen with dolutegravir plus lamivudine for HIV treatment in children: a narrative reviewClaudia Bartalucci, Laura Labate, Lucia Taramasso, et al.Clinical Case Reports|August 25, 2021
Kaposi-Juliusberg Varicelliform Eruption complicating Darier disease: May cannabinoid abuse be an underestimated risk factor?Roberto Russo, Laura Labate, Emanuele Cozzani, et al.The New Microbiologica|May 3, 2024
Lamivudine plus dolutegravir as a switch strategy in children: three case reportsLaura Labate, Claudia Bartalucci, Lucia Taramasso, et al.The New Microbiologica|May 29, 2023
PRESTIGIO RING: "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir"Laura Labate, Bianca Bruzzone, Vincenzo Spagnuolo, et al.Health Science Reports|July 22, 2025
Safe Switch to an Oral Two-Drug Regimen Based on Dolutegravir in People With Vertically Acquired HIV-1: An Observational Multicenter StudyGiulia Meraviglia, Anna Sala, Francesco Bassani, et al.Pageof 3